Kymera Therapeutics, Inc. - Common Stock (KYMR)

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.

This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.

Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.

Kymera Therapeutics develops targeted protein degradation therapies for immunology, oncology, and fibrosis using proprietary technology.

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.

Stocks slipped from record levels on Monday as investors shifted into “wait-and-see” mode ahead of Wednesday’s Fed decision. At the same time, Hollywood turned into a live-fire M&A battlefield, with Paramount Skydance crashing Netflix’s party for Warner Bros. Discovery and IBM writing a big AI-data check for Confluent.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

Kymera Therapeutics stated that its BroADen clinical trial of KT-621 showed that it achieved median reductions of STAT6 degradation of 94% and 98% in skin and blood in 100mg and 200mg dose groups.

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Kymera (KYMR) Q3 2025 Earnings Call Transcript

Kymera Therapeutics stock rises on positive clinical updates for its atopic dermatitis drug, KT-621, despite missing Q3 2025 revenue and EPS estimates.

Kymera Therapeutics Q2 2025 earnings miss estimates with $11.48M revenue (-55% YoY) and $0.95 EPS loss. Stock drops 2.7% pre-market despite clinical progress in STAT6 candidate.

Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime Report Final Trades discussed SNV, IYF, NEE-PR, and GILD.